Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Italian Start-up CellPly Snares $2.8M Seed Investment

Italian Start-up CellPly Snares $2.8M Seed Investment

Mar 21, 2014
|
staff reporter

NEW YORK (GenomeWeb News) – Start-up CellPly has attracted €2 million ($2.8 million) in seed capital investment to support development of its technology for determining patient response to oncology therapeutics.

Italian Angels for Growth, Zernike Meta Ventures, and Atlas Seed made the investment into Bologna, Italy-based CellPly in order to support the firm's completion of its diagnostics platform, which is being developed to allow clinicians to assess in vitro a patient's cellular response to cancer treatments, such as chemotherapy and monoclonal antibodies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Swabs for Science of Spread

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

Genome of the Murder Hornet

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

In a Pool Together

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

Science Presents Paper on Computational Method to Predict IBD Patient Response to Therapy

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

What's Popular?

In Cancer

  1. Guardant Health CDx Wins FDA Approval for First Liquid Biopsy NGS Tumor Profiling Assay

  2. Rakuten Medical Sues Illumina Over Trademark Dispute

  3. Guardant Health Q2 Revenues Rise 23 Percent

  4. Natera Files Additional Patent Infringement Lawsuit Against ArcherDx

  5. Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.